Top

Reviews in Endocrine and Metabolic Disorders

Published in:

01-03-2020 | Magnetic Resonance Imaging

Dynamic changes of views on the brain changes of Cushing’s syndrome using different computer-assisted tool

Authors: Lu Gao, Lu Liu, Lin Shi, Yishan Luo, Zihao Wang, Xiaopeng Guo, Bing Xing

Published in: Reviews in Endocrine and Metabolic Disorders | Issue 1/2020

Abstract

Cushing’s syndrome (CS) provides a unique model for assessing the neurotoxic effect of chronic hypercortisolism on human brains. With the ongoing development of different computer-assisted tools, four research stages emerged, each with its own pearls and pitfalls. This review summarizes current knowledge and describes the dynamic changes of views on the brain changes of CS, especially in the current era of the rapid development of artificial intelligence and big data. The adverse effects of GC on brain are proven to be on structural, functional and cellular levels at the same time.

Feelders RA, Newell-Price J, Pivonello R, Nieman LK, Hofland LJ, Lacroix A. Advances in the medical treatment of Cushing’s syndrome. Lancet Diabetes Endocrinol. 2019;7(4):300–12. https://doi.org/10.1016/S2213-8587(18)30155-4.CrossRefPubMed

Pivonello R, Isidori AM, De Martino MC, Newell-Price J, Biller BM, Colao A. Complications of Cushing’s syndrome: state of the art. Lancet Diabetes Endocrinol. 2016;4(7):611–29. https://doi.org/10.1016/S2213-8587(16)00086-3.CrossRefPubMed

Lacroix A, Feelders RA, Stratakis CA, Nieman LK. Cushing’s syndrome. Lancet. 2015;386(9996):913–27. https://doi.org/10.1016/S0140-6736(14)61375-1.CrossRefPubMed

Lonser RR, Nieman L, Oldfield EH. Cushing’s disease: pathobiology, diagnosis, and management. J Neurosurg. 2017;126(2):404–17. https://doi.org/10.3171/2016.1.JNS152119.CrossRefPubMed

Carroll TB, Findling JW. The diagnosis of Cushing’s syndrome. Rev Endocr Metab Disord. 2010;11(2):147–53. https://doi.org/10.1007/s11154-010-9143-3.CrossRefPubMed

Pivonello R, Simeoli C, De Martino MC, Cozzolino A, De Leo M, Iacuaniello D, et al. Neuropsychiatric disorders in Cushing’s syndrome. Front Neurosci. 2015;9:129. https://doi.org/10.3389/fnins.2015.00129.CrossRefPubMedPubMedCentral

Sonino N, Fava GA. Psychiatric disorders associated with Cushing’s syndrome. Epidemiology, pathophysiology and treatment. CNS Drugs. 2001;15(5):361–73. https://doi.org/10.2165/00023210-200115050-00003.CrossRefPubMed

Andela CD, van Haalen FM, Ragnarsson O, Papakokkinou E, Johannsson G, Santos A, et al. MECHANISMS IN ENDOCRINOLOGY: Cushing's syndrome causes irreversible effects on the human brain: a systematic review of structural and functional magnetic resonance imaging studies. Eur J Endocrinol. 2015;173(1):R1–14. https://doi.org/10.1530/EJE-14-1101.CrossRefPubMed

Cheng H, Gao L, Hou B, Feng F, Guo X, Wang Z, et al. Reversibility of cerebral blood flow in patients with Cushing’s disease after surgery treatment. Metabolism. 2019;104:154050. https://doi.org/10.1016/j.metabol.2019.154050.

10.

Hou B, Gao L, Shi L, Luo Y, Guo X, Young GS, et al. Reversibility of impaired brain structures after transsphenoidal surgery in Cushing’s disease: a longitudinal study based on an artificial intelligence-assisted tool. J Neurosurg. 2020:1-10. https://doi.org/10.3171/2019.10.JNS191400.

11.

de Kloet ER, Meijer OC, de Nicola AF, de Rijk RH, Joels M. Importance of the brain corticosteroid receptor balance in metaplasticity, cognitive performance and neuro-inflammation. Front Neuroendocrinol. 2018;49:124–45. https://doi.org/10.1016/j.yfrne.2018.02.003.CrossRefPubMed

12.

Forget H, Lacroix A, Somma M, Cohen H. Cognitive decline in patients with Cushing’s syndrome. J Int Neuropsychol Soc. 2000;6(1):20–9. https://doi.org/10.1017/s1355617700611037.CrossRefPubMed

13.

AbdelMannan D, Selman WR, Arafah BM. Peri-operative management of Cushing’s disease. Rev Endocr Metab Disord. 2010;11(2):127–34. https://doi.org/10.1007/s11154-010-9140-6.CrossRefPubMed

14.

Nieman LK, Biller BM, Findling JW, Murad MH, Newell-Price J, Savage MO, et al. Treatment of Cushing’s syndrome: an endocrine society clinical practice guideline. J Clin Endocrinol Metab. 2015;100(8):2807–31. https://doi.org/10.1210/jc.2015-1818.CrossRefPubMedPubMedCentral

15.

Feng M, Liu Z, Liu X, Bao X, Yao Y, Deng K, et al. Diagnosis and outcomes of 341 patients with Cushing’s disease following transsphenoid surgery: a single-center experience. World Neurosurg. 2018;109:e75–80. https://doi.org/10.1016/j.wneu.2017.09.105.CrossRefPubMed

16.

Resmini E, Santos A, Gomez-Anson B, Vives Y, Pires P, Crespo I, et al. Verbal and visual memory performance and hippocampal volumes, measured by 3-tesla magnetic resonance imaging, in patients with Cushing’s syndrome. J Clin Endocrinol Metab. 2012;97(2):663–71. https://doi.org/10.1210/jc.2011-2231.CrossRefPubMed

17.

Ragnarsson O, Berglund P, Eder DN, Johannsson G. Long-term cognitive impairments and attentional deficits in patients with Cushing’s disease and cortisol-producing adrenal adenoma in remission. J Clin Endocrinol Metab. 2012;97(9):E1640–8. https://doi.org/10.1210/jc.2012-1945.CrossRefPubMed

18.

Tiemensma J, Kokshoorn NE, Biermasz NR, Keijser BJ, Wassenaar MJ, Middelkoop HA, et al. Subtle cognitive impairments in patients with long-term cure of Cushing’s disease. J Clin Endocrinol Metab. 2010;95(6):2699–714. https://doi.org/10.1210/jc.2009-2032.CrossRefPubMed

19.

van Aken MO, Pereira AM, Biermasz NR, van Thiel SW, Hoftijzer HC, Smit JW, et al. Quality of life in patients after long-term biochemical cure of Cushing’s disease. J Clin Endocrinol Metab. 2005;90(6):3279–86. https://doi.org/10.1210/jc.2004-1375.CrossRefPubMed

20.

Stomby A, Salami A, Dahlqvist P, Evang JA, Ryberg M, Bollerslev J, et al. Elevated resting-state connectivity in the medial temporal lobe and the prefrontal cortex among patients with Cushing’s syndrome in remission. Eur J Endocrinol. 2019;180(5):329–38. https://doi.org/10.1530/EJE-19-0028.CrossRefPubMed

21.

van der Werff SJ, Pannekoek JN, Andela CD, Meijer OC, van Buchem MA, Rombouts SA, et al. Resting-state functional connectivity in patients with long-term remission of Cushing’s disease. Neuropsychopharmacology. 2015;40(8):1888–98. https://doi.org/10.1038/npp.2015.38.CrossRefPubMedPubMedCentral

22.

Steward T, Miranda-Olivos R, Soriano-Mas C, Fernandez-Aranda F. Neuroendocrinological mechanisms underlying impulsive and compulsive behaviors in obesity: a narrative review of fMRI studies. Rev Endocr Metab Disord. 2019;20(3):263–72. https://doi.org/10.1007/s11154-019-09515-x.CrossRefPubMed

23.

van der Werff SJ, Andela CD, Nienke Pannekoek J, Meijer OC, van Buchem MA, Rombouts SA, et al. Widespread reductions of white matter integrity in patients with long-term remission of Cushing’s disease. NeuroImage Clin. 2014;4:659–67. https://doi.org/10.1016/j.nicl.2014.01.017.CrossRefPubMedPubMedCentral

24.

Jiang H, Ren J, He NY, Liu C, Sun YH, Jian FF, et al. Volumetric magnetic resonance imaging analysis in patients with short-term remission of Cushing’s disease. Clin Endocrinol. 2017;87(4):367–74. https://doi.org/10.1111/cen.13381.CrossRef

25.

Gordan GS, Elliott HW. The action of diethylstilbestrol and some steroids on the respiration of rat brain homogenates. Endocrinology. 1947;41(6):517. https://doi.org/10.1210/endo-41-6-517.CrossRefPubMed

26.

Woodbury DM, Emmett JW, Hinckley GV, Jackson NR, Newton JD, Bateman JH, et al. Antagonism of adrenocortical extract and cortisone to desoxycorticosterone; brain excitability in adrenalectomized rats. Proc Soc Exp Biol Med. 1951;76(1):65–8. https://doi.org/10.3181/00379727-76-18389.CrossRefPubMed

27.

Woodbury DM, Sayers G. Effect of adrenocorticotrophic hormone cortisone and desoxycorticosterone on brain excitability. Proc Soc Exp Biol Med. 1950;75(2):398–403. https://doi.org/10.3181/00379727-75-18211.CrossRefPubMed

28.

De Kloet ER, Vreugdenhil E, Oitzl MS, Joels M. Brain corticosteroid receptor balance in health and disease. Endocr Rev. 1998;19(3):269–301. https://doi.org/10.1210/edrv.19.3.0331.CrossRefPubMed

29.

Sapolsky RM, Uno H, Rebert CS, Finch CE. Hippocampal damage associated with prolonged glucocorticoid exposure in primates. J Neurosci. 1990;10(9):2897–902.CrossRef

30.

Schubert MI, Kalisch R, Sotiropoulos I, Catania C, Sousa N, Almeida OF, et al. Effects of altered corticosteroid milieu on rat hippocampal neurochemistry and structure--an in vivo magnetic resonance spectroscopy and imaging study. J Psychiatr Res. 2008;42(11):902–12. https://doi.org/10.1016/j.jpsychires.2007.10.003.CrossRefPubMed

31.

Cerqueira JJ, Catania C, Sotiropoulos I, Schubert M, Kalisch R, Almeida OF, et al. Corticosteroid status influences the volume of the rat cingulate cortex - a magnetic resonance imaging study. J Psychiatr Res. 2005;39(5):451–60. https://doi.org/10.1016/j.jpsychires.2005.01.003.CrossRefPubMed

32.

Trethowan WH, Cobb S. Neuropsychiatric aspects of Cushing’s syndrome. AMA Arch Neurol Psychiatry. 1952;67(3):283–309. https://doi.org/10.1001/archneurpsyc.1952.02320150016002.CrossRefPubMed

33.

Momose KJ, Kjellberg RN, Kliman B. High incidence of cortical atrophy of the cerebral and cerebellar hemispheres in Cushing’s disease. Radiology. 1971;99(2):341–8. https://doi.org/10.1148/99.2.341.CrossRefPubMed

34.

Starkman MN, Gebarski SS, Berent S, Schteingart DE. Hippocampal formation volume, memory dysfunction, and cortisol levels in patients with Cushing’s syndrome. Biol Psychiatry. 1992;32(9):756–65. https://doi.org/10.1016/0006-3223(92)90079-f.CrossRefPubMed

35.

Starkman MN, Giordani B, Gebarski SS, Berent S, Schork MA, Schteingart DE. Decrease in cortisol reverses human hippocampal atrophy following treatment of Cushing’s disease. Biol Psychiatry. 1999;46(12):1595–602. https://doi.org/10.1016/s0006-3223(99)00203-6.CrossRefPubMed

36.

Starkman MN, Giordani B, Gebarski SS, Schteingart DE. Improvement in mood and ideation associated with increase in right caudate volume. J Affect Disord. 2007;101(1–3):139–47. https://doi.org/10.1016/j.jad.2006.11.007.CrossRefPubMed

37.

Toffanin T, Nifosi F, Follador H, Passamani A, Zonta F, Ferri G, et al. Volumetric MRI analysis of hippocampal subregions in Cushing’s disease: a model for glucocorticoid neural modulation.Eur Psychiatry. 2011;26(1):64–7. https://doi.org/10.1016/j.eurpsy.2010.09.003.CrossRefPubMed

38.

Bourdeau I, Bard C, Noel B, Leclerc I, Cordeau MP, Belair M, et al. Loss of brain volume in endogenous Cushing’s syndrome and its reversibility after correction of hypercortisolism. J Clin Endocrinol Metab. 2002;87(5):1949–54. https://doi.org/10.1210/jcem.87.5.8493.CrossRefPubMed

39.

Hook JN, Giordani B, Schteingart DE, Guire K, Giles J, Ryan K, et al. Patterns of cognitive change over time and relationship to age following successful treatment of Cushing’s disease. J Int Neuropsychol Soc. 2007;13(1):21–9. https://doi.org/10.1017/S1355617707070051.CrossRefPubMed

40.

Starkman MN, Giordani B, Gebarski SS, Schteingart DE. Improvement in learning associated with increase in hippocampal formation volume. Biol Psychiatry. 2003;53(3):233–8. https://doi.org/10.1016/s0006-3223(02)01750-x.CrossRefPubMed

41.

Khiat A, Bard C, Lacroix A, Rousseau J, Boulanger Y. Brain metabolic alterations in Cushing’s syndrome as monitored by proton magnetic resonance spectroscopy. NMR Biomed. 1999;12(6):357–63. https://doi.org/10.1002/(sici)1099-1492(199910)12:6<357::aid-nbm584>3.0.co;2-u.

42.

Khiat A, Bard C, Lacroix A, Boulanger Y. Recovery of the brain choline level in treated Cushing’s patients as monitored by proton magnetic resonance spectroscopy. Brain Res. 2000;862(1–2):301–7. https://doi.org/10.1016/s0006-8993(00)02147-8.CrossRefPubMed

43.

Simmons NE, Do HM, Lipper MH, Laws ER Jr. Cerebral atrophy in Cushing’s disease. Surg Neurol. 2000;53(1):72–6. https://doi.org/10.1016/s0090-3019(99)00197-4.CrossRefPubMed

44.

Merke DP, Giedd JN, Keil MF, Mehlinger SL, Wiggs EA, Holzer S, et al. Children experience cognitive decline despite reversal of brain atrophy one year after resolution of Cushing syndrome. J Clin Endocrinol Metab. 2005;90(5):2531–6. https://doi.org/10.1210/jc.2004-2488.CrossRefPubMed

45.

Ashburner J, Friston KJ. Voxel-based morphometry--the methods. NeuroImage. 2000;11(6 Pt 1):805–21. https://doi.org/10.1006/nimg.2000.0582.CrossRefPubMed

46.

Andela CD, van der Werff SJ, Pannekoek JN, van den Berg SM, Meijer OC, van Buchem MA, et al. Smaller grey matter volumes in the anterior cingulate cortex and greater cerebellar volumes in patients with long-term remission of Cushing’s disease: a case-control study. Eur J Endocrinol. 2013;169(6):811–9. https://doi.org/10.1530/EJE-13-0471.CrossRefPubMed

47.

Burkhardt T, Ludecke D, Spies L, Wittmann L, Westphal M, Flitsch J. Hippocampal and cerebellar atrophy in patients with Cushing’s disease. Neurosurg Focus. 2015;39(5):E5. https://doi.org/10.3171/2015.8.FOCUS15324.CrossRefPubMed

48.

Jiang H, He NY, Sun YH, Jian FF, Bian LG, Shen JK, et al. Altered gray and white matter microstructure in Cushing’s disease: a diffusional kurtosis imaging study. Brain Res. 1665;2017:80–7. https://doi.org/10.1016/j.brainres.2017.04.007.CrossRef

49.

Josephs KA, Dickson DW, Tosakulwong N, Weigand SD, Murray ME, Petrucelli L, et al. Rates of hippocampal atrophy and presence of post-mortem TDP-43 in patients with Alzheimer’s disease: a longitudinal retrospective study. Lancet Neurol. 2017;16(11):917–24. https://doi.org/10.1016/S1474-4422(17)30284-3.CrossRefPubMedPubMedCentral

50.

Resmini E, Santos A, Gomez-Anson B, Lopez-Mourelo O, Pires P, Vives-Gilabert Y, et al. Hippocampal dysfunction in cured Cushing’s syndrome patients, detected by (1) H-MR-spectroscopy. Clin Endocrinol. 2013;79(5):700–7. https://doi.org/10.1111/cen.12224.CrossRef

51.

Santos A, Resmini E, Crespo I, Pires P, Vives-Gilabert Y, Granell E, et al. Small cerebellar cortex volume in patients with active Cushing’s syndrome. Eur J Endocrinol. 2014;171(4):461–9. https://doi.org/10.1530/EJE-14-0371.CrossRefPubMed

52.

Crespo I, Esther GM, Santos A, Valassi E, Yolanda VG, De Juan-Delago M, et al. Impaired decision-making and selective cortical frontal thinning in Cushing’s syndrome. Clin Endocrinol. 2014;81(6):826–33. https://doi.org/10.1111/cen.12564.CrossRef

53.

Santos A, Granell E, Gomez-Anson B, Crespo I, Pires P, Vives-Gilabert Y, et al. Depression and anxiety scores are associated with amygdala volume in Cushing’s syndrome: preliminary study. Biomed Res Int. 2017;2017:2061935. https://doi.org/10.1155/2017/2061935.CrossRefPubMedPubMedCentral

54.

Crespo I, Santos A, Gomez-Anson B, Lopez-Mourelo O, Pires P, Vives-Gilabert Y, et al. Brain metabolite abnormalities in ventromedial prefrontal cortex are related to duration of hypercortisolism and anxiety in patients with Cushing’s syndrome. Endocrine. 2016;53(3):848–56. https://doi.org/10.1007/s12020-016-0963-0.CrossRefPubMed

55.

Abrigo J, Shi L, Luo Y, Chen Q, Chu WCW, Mok VCT, et al. Standardization of hippocampus volumetry using automated brain structure volumetry tool for an initial Alzheimer’s disease imaging biomarker. Acta Radiol. 2019;60(6):769–76. https://doi.org/10.1177/0284185118795327.CrossRefPubMed

56.

Kanevsky J, Corban J, Gaster R, Kanevsky A, Lin S, Gilardino M. Big data and machine learning in plastic surgery: a new frontier in surgical innovation. Plast Reconstr Surg. 2016;137(5):890e–7e. https://doi.org/10.1097/PRS.0000000000002088.CrossRefPubMed

57.

Shin HC, Roth HR, Gao M, Lu L, Xu Z, Nogues I, et al. Deep convolutional neural networks for computer-aided detection: CNN architectures, dataset characteristics and transfer learning. IEEE Trans Med Imaging. 2016;35(5):1285–98. https://doi.org/10.1109/TMI.2016.2528162.CrossRefPubMed

58.

LeCun Y, Bengio Y, Hinton G. Deep learning. Nature. 2015;521(7553):436–44. https://doi.org/10.1038/nature14539.CrossRef

59.

Wang C, Zhao L, Luo Y, Liu J, Miao P, Wei S, et al. Structural covariance in subcortical stroke patients measured by automated MRI-based volumetry. NeuroImage Clin. 2019;22:101682. https://doi.org/10.1016/j.nicl.2019.101682.CrossRefPubMedPubMedCentral

60.

Frisoni GB, Jack CR Jr, Bocchetta M, Bauer C, Frederiksen KS, Liu Y, et al. The EADC-ADNI harmonized protocol for manual hippocampal segmentation on magnetic resonance: evidence of validity.Alzheimers Dement. 2015;11(2):111–25. https://doi.org/10.1016/j.jalz.2014.05.1756.CrossRefPubMed

61.

Zhao W, Luo Y, Zhao L, Mok V, Su L, Yin C, et al. Automated brain MRI Volumetry differentiates early stages of Alzheimer’s disease from normal aging. J Geriatr Psychiatry Neurol. 2019;32(6):354–64. https://doi.org/10.1177/0891988719862637.CrossRefPubMed

62.

Maheu FS, Mazzone L, Merke DP, Keil MF, Stratakis CA, Pine DS, et al. Altered amygdala and hippocampus function in adolescents with hypercortisolemia: a functional magnetic resonance imaging study of Cushing syndrome. Dev Psychopathol. 2008;20(4):1177–89. https://doi.org/10.1017/S0954579408000564.CrossRefPubMedPubMedCentral

63.

Langenecker SA, Weisenbach SL, Giordani B, Briceno EM, Guidotti Breting LM, Schallmo MP, et al. Impact of chronic hypercortisolemia on affective processing. Neuropharmacology. 2012;62(1):217–25. https://doi.org/10.1016/j.neuropharm.2011.07.006.CrossRefPubMed

64.

Bas-Hoogendam JM, Andela CD, van der Werff SJ, Pannekoek JN, van Steenbergen H, Meijer OC, et al. Altered neural processing of emotional faces in remitted Cushing’s disease. Psychoneuroendocrinology. 2015;59:134–46. https://doi.org/10.1016/j.psyneuen.2015.05.001.CrossRefPubMed

65.

Kim MJ, Loucks RA, Palmer AL, Brown AC, Solomon KM, Marchante AN, et al. The structural and functional connectivity of the amygdala: from normal emotion to pathological anxiety. Behav Brain Res. 2011;223(2):403–10. https://doi.org/10.1016/j.bbr.2011.04.025.CrossRefPubMedPubMedCentral

66.

Leech R, Sharp DJ. The role of the posterior cingulate cortex in cognition and disease. Brain : a journal of neurology. 2014;137(Pt 1):12–32. https://doi.org/10.1093/brain/awt162.CrossRef

67.

Khalsa S, Mayhew SD, Chechlacz M, Bagary M, Bagshaw AP. The structural and functional connectivity of the posterior cingulate cortex: comparison between deterministic and probabilistic tractography for the investigation of structure-function relationships. NeuroImage. 2014;102(Pt 1):118–27. https://doi.org/10.1016/j.neuroimage.2013.12.022.CrossRefPubMed

68.

van den Heuvel M, Mandl R, Luigjes J, Hulshoff PH. Microstructural organization of the cingulum tract and the level of default mode functional connectivity. J Neurosci. 2008;28(43):10844–51. https://doi.org/10.1523/JNEUROSCI.2964-08.2008.CrossRefPubMedPubMedCentral

69.

Ragnarsson O, Stomby A, Dahlqvist P, Evang JA, Ryberg M, Olsson T, et al. Decreased prefrontal functional brain response during memory testing in women with Cushing’s syndrome in remission. Psychoneuroendocrinology. 2017;82:117–25. https://doi.org/10.1016/j.psyneuen.2017.05.010.CrossRefPubMed

70.

Biswal BB, Mennes M, Zuo XN, Gohel S, Kelly C, Smith SM, et al. Toward discovery science of human brain function. Proc Natl Acad Sci U S A. 2010;107(10):4734–9. https://doi.org/10.1073/pnas.0911855107.CrossRefPubMedPubMedCentral

71.

Biswal B, Yetkin FZ, Haughton VM, Hyde JS. Functional connectivity in the motor cortex of resting human brain using echo-planar MRI. Magn Reson Med. 1995;34(4):537–41. https://doi.org/10.1002/mrm.1910340409.CrossRefPubMed

72.

Jiang H, He NY, Sun YH, Jian FF, Bian LG, Shen JK, et al. Altered spontaneous brain activity in Cushing’s disease: a resting-state functional MRI study. Clin Endocrinol. 2017;86(3):367–76. https://doi.org/10.1111/cen.13277.CrossRef

73.

Wang X, Zhou T, Wang P, Zhang L, Feng S, Meng X, et al. Dysregulation of resting-state functional connectivity in patients with Cushing’s disease. Neuroradiology. 2019;61(8):911–20. https://doi.org/10.1007/s00234-019-02223-y.CrossRefPubMed

74.

Johansen-Berg H, Rushworth MF. Using diffusion imaging to study human connectional anatomy. Annu Rev Neurosci. 2009;32:75–94. https://doi.org/10.1146/annurev.neuro.051508.135735.CrossRefPubMed

75.

Pires P, Santos A, Vives-Gilabert Y, Webb SM, Sainz-Ruiz A, Resmini E, et al. White matter alterations in the brains of patients with active, remitted, and cured Cushing syndrome: a DTI study. AJNR Am J Neuroradiol. 2015;36(6):1043–8. https://doi.org/10.3174/ajnr.A4322.CrossRefPubMed

76.

Alexander AL, Lee JE, Lazar M, Field AS. Diffusion tensor imaging of the brain. Neurotherapeutics. 2007;4(3):316–29. https://doi.org/10.1016/j.nurt.2007.05.011.CrossRefPubMedPubMedCentral

77.

Sorrells SF, Sapolsky RM. An inflammatory review of glucocorticoid actions in the CNS. Brain Behav Immun. 2007;21(3):259–72. https://doi.org/10.1016/j.bbi.2006.11.006.CrossRefPubMed

78.

Liu S, Wang Y, Xu K, Ping F, Li F, Wang R, et al. Voxel-based comparison of brain glucose metabolism between patients with Cushing’s disease and healthy subjects. NeuroImage Clin. 2018;17:354–8. https://doi.org/10.1016/j.nicl.2017.10.038.CrossRefPubMed

79.

Liu S, Wang Y, Xu K, Ping F, Wang R, Li F, et al. Brain glucose metabolism is associated with hormone level in Cushing’s disease: a voxel-based study using FDG-PET. NeuroImage Clin. 2016;12:415–9. https://doi.org/10.1016/j.nicl.2016.08.018.CrossRefPubMedPubMedCentral

80.

Buckner RL, Andrews-Hanna JR, Schacter DL. The brain’s default network: anatomy, function, and relevance to disease. Ann N Y Acad Sci. 2008;1124:1–38. https://doi.org/10.1196/annals.1440.011.CrossRefPubMed

Title: Dynamic changes of views on the brain changes of Cushing’s syndrome using different computer-assisted tool
Authors: Lu Gao
Lu Liu
Lin Shi
Yishan Luo
Zihao Wang
Xiaopeng Guo
Bing Xing
Publication date: 01-03-2020
Publisher: Springer US
Keywords: Magnetic Resonance Imaging
Magnetic Resonance Imaging
Cushing's Syndrome
Artificial Intelligence
Glucocorticoid
Published in: Reviews in Endocrine and Metabolic Disorders / Issue 1/2020
Print ISSN: 1389-9155
Electronic ISSN: 1573-2606
DOI: https://doi.org/10.1007/s11154-020-09540-1

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits

Illustration of figure on mountain summit/© Orapun / Stock.adobe.com, STEP AAG HeroTeaserCollection image/© Tarek / Generated with AI / Stock.adobe.com, ACC 2024 Pediatric and Congenital Heart Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 Pulmonary Vascular Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 Valvular Heart Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 HF and Cardiomyopathies: Year in Review/© 2024 American College of Cardiology, Woman out walking/© Seventyfour / stock.adobe.com (symbolic image with model), Woman checking smartwatch /© saltdium / stock.adobe.com (symbolic image with model), Cardiac catheterization/© Damian / stock.adobe.com

At a glance: The STEP trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 1/2020

Obesity and overweight decreases the effect of vitamin D supplementation in adults: systematic review and meta-analysis of randomized controlled trials

Effects of time-restricted feeding on body weight and metabolism. A systematic review and meta-analysis

A clinical perspective of parathyroid hormone related hypercalcaemia

Efficacy and safety of very low calorie ketogenic diet (VLCKD) in patients with overweight and obesity: A systematic review and meta-analysis

Endocrine disrupting chemicals: exposure, effects on human health, mechanism of action, models for testing and strategies for prevention

Correction to: Effects of time-restricted feeding on body weight and metabolism. A systematic review and meta-analysis

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

Highlights from the ACC 2024 Congress

ACC 2024 Congress Coverage